ResMed (RMD) continues to garner attention as the blended valuation of the company continues to rise along with its share price. Multiple investment firms are adjusting positions, with firms such as Inspire Investing LLC, Triodos Investment Management BV, and Prime Capital Investment Advisors LLC lowering their stakes, while others like L. Roy Papp & Associates LLP, KLP Kapitalforvaltning AS, and TriaGen Wealth Management LLC have increased their holdings. Also notable is the
$2.13 Million investment made by Lindenwold Advisors INC. Analyst consensus rates RMD as a moderate buy, and their FY2026 Q1 results are expected on October 30, 2025. Meanwhile, a U.S. probe into medical device imports could impact the bullish sentiment around ResMed. The company is also earning accolades as a top growth and momentum stock. Amid all this, ResMed's CEO sold 8,009 shares of his RMD stock, and the company is preparing to launch the
Global Sleep Institute while continuing to show strong revenue growth reflected in record high Q4 earnings.
Overall, the narrative is dominated by the company's strategic growth, investment interests, and substantial market presence. However, future prospects are awaited as market analysts evaluate the company's first-quarter fiscal 2026 earnings release.
Resmed RMD News Analytics from Mon, 17 Mar 2025 07:00:00 GMT to Sat, 11 Oct 2025 10:50:11 GMT -
Rating 6
- Innovation 6
- Information 8
- Rumor -3
